Other

Financing Receivables, After Allowance For Credit Loss Changes In Expected Cash Flows

Royalty Pharma Financing Receivables, After Allowance For Credit Loss Changes In Expected Cash Flows increased by 1.5% to $17.53B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 9.7%, from $15.97B to $17.53B. Over 5 years (FY 2020 to FY 2025), Financing Receivables, After Allowance For Credit Loss Changes In Expected Cash Flows shows an upward trend with a 5.4% CAGR.

Analysis

StatementBalance Sheet Statement
SectionOther
First reportedQ2 2020
Last reportedQ1 2026
Metric ID: other_financing_receivables_after_allowance_for_credit_l_270b9e

Historical Data

20 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$13.89B$14.89B$14.64B$14.30B$14.31B$15.16B$14.30B$14.39B$14.11B$14.12B$14.96B$14.26B$14.81B$15.94B$16.15B$15.97B$16.19B$16.84B$17.27B$17.53B
QoQ Change—+7.2%-1.7%-2.4%+0.1%+5.9%-5.6%+0.7%-1.9%+0.0%+6.0%-4.7%+3.8%+7.6%+1.3%-1.1%+1.4%+4.0%+2.6%+1.5%
YoY Change————+3.0%+1.8%-2.3%+0.7%-1.4%-6.8%+4.7%-0.9%+4.9%+12.9%+7.9%+12.0%+9.4%+5.7%+7.0%+9.7%
Range$13.89B – $17.53B
CAGR+5.0%
Avg YoY Growth+4.3%
Median YoY Growth+4.8%
Current Streak4 quarters growth

Frequently Asked Questions

What is Royalty Pharma's financing receivables, after allowance for credit loss changes in expected cash flows?
Royalty Pharma (RPRX) reported financing receivables, after allowance for credit loss changes in expected cash flows of $17.53B in Q1 2026.
How has Royalty Pharma's financing receivables, after allowance for credit loss changes in expected cash flows changed year-over-year?
Royalty Pharma's financing receivables, after allowance for credit loss changes in expected cash flows increased by 9.7% year-over-year, from $15.97B to $17.53B.
What is the long-term trend for Royalty Pharma's financing receivables, after allowance for credit loss changes in expected cash flows?
Over 5 years (2020 to 2025), Royalty Pharma's financing receivables, after allowance for credit loss changes in expected cash flows has grown at a 5.4% compound annual growth rate (CAGR), from $13.28B to $17.27B.